Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-804 versus placebo in previously treated advanced non-small cell lung cancer
ACTRN12610000312044Phase 3Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Apr 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing PF-804 with Placebo (2 arms). Primary endpoint: Overall survival. Started Apr 2010; status: recruiting.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12610000312044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000312044.